Obalon Therapeutics P/E Ratio

Obalon Therapeutics (OBLN) currently reports a P/E ratio of 9.53. That is below the Healthcare sector average of 26.85. Use the charts on this page to explore Obalon Therapeutics's P/E ratio history and peer comparisons.

Obalon Therapeutics's P/E ratio of 9.53 is lower than the Healthcare sector average of 26.85. That is roughly 64.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Obalon Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 9.53, OBLN can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 9.53, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.85. From there, open related valuation or income-statement pages for Obalon Therapeutics, and consider following OBLN for alerts when major investors trade the stock.

Obalon Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows 9.53 versus a sector average near 26.85. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing OBLN with unrelated industries.